FSLR
52
-3
GM
44
-3
GPC
35
-2
LH
43
-2
LRCX
55
-6
QCOM
50
-2
SYF
62
-5
CAT
44
-4
PEG
53
-4
AIV
46
3
DD
36
-2
GILD
49
2
ADT
38
-5
BLK
40
-6
MKC
47
-6
DUK
55
-4
PYPL
43
-13
APD
50
5
MPC
36
-2
CL
43
-5
FSLR
52
-3
GM
44
-3
GPC
35
-2
LH
43
-2
LRCX
55
-6
QCOM
50
-2
SYF
62
-5
CAT
44
-4
PEG
53
-4
AIV
46
3
DD
36
-2
GILD
49
2
ADT
38
-5
BLK
40
-6
MKC
47
-6
DUK
55
-4
PYPL
43
-13
APD
50
5
MPC
36
-2
CL
43
-5
Financhill
Back

Cyclo Therapeutics 10K Form

Sell
24

CYTH
Cyclo Therapeutics

Last Price:
$0.63
Seasonality Move:
31.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CYTH News And Ratings

See the #1 stock for the next 7 days that we like better than CYTH

CYTH Financial Statistics

Sales & Book Value

Annual Sales: $1.1M
Cash Flow: $-8.2M
Price / Cash Flow: 0
Annual Sales: $-0.47
Price / Book: 68.02

Profitability

EPS (TTM): -0.90000
Net Income (TTM): $-24.8M
Gross Margin: $992K
Return on Equity: -4056.09%
Return on Assets: -344.63%

Cyclo Therapeutics Earnings Forecast

Key Cyclo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 24 years for CYTH is 92.16%.
  • The Selling, General & Administrative Expenses for CYTH have been equal to 526.37% of Gross Profit Margin.
  • The Research & Development expenses have been 1,317.51% of Revenue.
  • The Net Earning history of CYTH is -1,863.35% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 14 years.

Cyclo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CYTH
Website: cyclotherapeutics.com

Debt

Debt-to-Equity Ratio: -0.9
Current Ratio: 0.17
Quick Ratio: 0.06

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CYTH Technical Analysis vs Fundamental Analysis

Sell
24
Cyclo Therapeutics (CYTH) is a Sell

Is Cyclo Therapeutics a Buy or a Sell?